

## 1 Online materials and methods

2 **Study design.** This report is part of the COLOBILI study – Coronavirus Longitudinal Biomarkers in  
3 Lung Injury, being conducted at St. Michael’s Hospital (Toronto, ON, Canada). This is an  
4 observational cohort study that includes analysis of biological samples. The study was approved  
5 by the Research Ethics Board of St. Michael’s Hospital (REB# 20-078). The inclusion criteria were  
6 all patients above age 18 years admitted to the Medical-Surgical or Trauma-Neuro intensive care  
7 units (ICU) with acute respiratory distress, suspected to have COVID-19. COVID-19 status was  
8 determined according to diagnostic PCR of nasopharyngeal swabs and/or endotracheal aspirates  
9 as described in detail below. The exclusion criteria were refusal to participate, inability to  
10 ascertain mortality status during the first 2 weeks of the study, failure to obtain a blood sample  
11 on either day 0 or 1, or individuals known to have had COVID-19 in the 4 weeks prior to admission  
12 in any setting. Patients were followed for up to 3 months in hospital or hospital discharge,  
13 whichever occurred first. The primary outcome was death in the ICU; secondary outcomes  
14 included death outside the ICU, ICU utilization metrics, and organ dysfunction measures and  
15 scores. Clinical data and blood samples were collected longitudinally immediately upon  
16 admission, as available, defined as day 0, and on the morning of days 1, 3, 5, 7 and 10; after day  
17 10 or ICU discharge, they were sampled every 2 weeks. The study started on March 26<sup>th</sup>, 2020,  
18 and the first patient was recruited on March 29<sup>th</sup>, 2020. The study is ongoing; the last patient from  
19 the cohort presented in this manuscript was recruited on May 17<sup>th</sup>, 2020, and the data was  
20 censored for analysis on May 31<sup>st</sup>, 2020. No COVID-19 treatments were given to the patients  
21 beyond the standard of care since at the time there was no evidence of efficacy for any such  
22 treatments. Informed consent was obtained from the patients or their legal representatives; in  
23 case that was not possible, the patients were enrolled using a deferred consent model and kept  
24 in the study until they regained capacity, or a surrogate decision maker was identified.

25 **Data and sample collection.** Demographics, clinical data and clinical laboratory were collected  
26 from the patients’ paper and electronic medical records, with auditing performed reciprocally by  
27 research coordination team members and curated by UT. To standardize handling and processing,  
28 blood samples were collected in EDTA tubes between 8:00 and 12:00 AM and kept on ice for up  
29 to 60 minutes until their processing in a dedicated translational research station located inside  
30 the ICU. They were then immediately frozen at -20 °C on site, and transferred to -80 °C for storage  
31 within 48 hrs. All procedures were performed by dedicated research personnel. Nasopharyngeal  
32 samples were obtained from all patients by bedside nurses and analyzed by the clinical laboratory

33 using either the Altona RealStar SARS-CoV-2 RT-PCR Kit 1.0 or Cepheid GeneXpert Xpert Xpress  
34 SARS-CoV-2 assay. Endotracheal tube aspirates were analyzed using the Seegene Allplex 2019-  
35 CoV Assay. All patients had a nasopharyngeal PCR performed; intubated patients had an  
36 endotracheal aspirate sent as well. Further PCR tests were repeated by the clinical and infection  
37 control teams at their discretion if there was suspicion of a false negative result based on clinical  
38 observations or to confirm negativity. All patients in the PCR negative cohort had at least two  
39 negative tests performed acutely, except one patient who had only one test done acutely. To  
40 analyze longitudinal trends, only patients with 3 or more longitudinal sampling times were  
41 included in the study. To mitigate bias, five patients with shorter ICU admissions were included;  
42 2 had early deaths and 3 had early discharges.

43 **Experimental procedures.** Plasma samples were stored and managed under a standard  
44 operating procedure which included shipping on dry ice and storage at -80C until assay  
45 performance by Mitogen Diagnostics Laboratory (MitogenDx, Calgary, AB, Canada). Anti-  
46 cardiolipin, anti- $\beta$ 2-GP1 and anti-PS/PT complex were tested for IgG and IgM, as well as IgG anti-  
47 domain 1  $\beta$ 2-GP1 – all by ELISA and chemiluminescence (Inova Diagnostics, San Diego, CA USA).  
48 A HEp-2 indirect immunofluorescence assay (IFA) was used to detect anti-cellular antibodies  
49 (also referred to as anti-nuclear antibodies (ANA) – see “nomenclature” below)<sup>1</sup> (NOVA Lite  
50 HEp-2, Inova Diagnostics, San Diego, CA) at a serum dilution of 1:80 and read on an automated  
51 instrument (Nova View, Inova Diagnostics) which interpolates fluorescence intensity to an end  
52 point titer<sup>2</sup>. IFA staining patterns were classified according to the International Consensus on  
53 Autoantibody Patterns (ICAP, <https://anapatterns.org/index.php>)<sup>3</sup>, and considered positive at a  
54 dilution  $\geq$ 1:160. All samples were also tested for systemic autoimmune disease-related  
55 autoantibodies by a FIDIS Connective13 addressable laser bead immunoassay (ALBIA)  
56 (TheraDiag, Paris, France) detecting antibodies to Sm/U2-U6 ribonucleoprotein (RNP), U1-RNP,  
57 SSA/Ro60, SSB/La, Ro52/Tripartite Motif Protein 21 (TRIM21), histones, and ribosomal P, read  
58 on a Luminex 200 system using the MLX-Booster software. A cut-off of >40 units was considered  
59 positive. Anti-dsDNA positivity and titers were detected by a chemiluminescence test (Inova  
60 Diagnostics, San Diego, USA). A cut-off of <27 chemiluminescence units was considered within  
61 normal range, 27-35 was indeterminate, and >35 was positive. All samples were also tested for  
62 autoantibodies associated with autoimmune inflammatory myopathies using a multiplexed solid  
63 phase line immunoassay: Ro-52/TRIM21, OJ, EJ, PL-12, PL-7, SRP, Jo-1, PM-75, PM-100, Ku,  
64 SAE1, NXP2, MDA5, TIF1 $\gamma$ , Mi-2 $\alpha$ , Mi-2 $\beta$  (Euroimmun AG, Luebeck, Germany), and anti-NT5c1A

65 by ALBIA<sup>4</sup>. The following anti-cytokine antibodies were assayed using an ALBIA (Millipore,  
66 Oakville, ON, Canada; HCYTAAB-17K-15) read on a Luminex 200 system: BAFF, GMCSF, IFN- $\beta$ ,  
67 IFN- $\gamma$ , IL-1a, IL-6, IL-8, IL-10, IL-12p40, IL-15, IL-17a, IL-17f, IL-18, IL-22 and TNF- $\alpha$ . The  
68 manufacturer's thresholds were 500 for positive and 1000 for high-positive (arbitrary units). All  
69 tests were performed according to the manufacturer's instructions.

70 **Nomenclature.** There is considerable heterogeneity in the nomenclature of autoimmune assays  
71 in the literature and clinical practice; therefore, we used the most contemporary usages.  
72 Autoantibodies is a general term that encompasses all of the autoimmune humoral responses  
73 assayed. The HEp-2 IFA, although including anti-cytoplasmic and anti-mitotic cell antibodies, are  
74 commonly referred as anti-nuclear antibodies (ANA), and we have adopted that usage for  
75 clarity. The AAB test results that identified specific, named antigens (see details above), were  
76 called collectively antigen-specific autoantibodies. We have further separated them into  
77 myositis-related and non-myositis-related AAB. Anti-cytokine autoantibodies are referred to  
78 directly.

79 **Data analysis.** All the data was organized and analyzed by UT. The data was censored on May 31<sup>st</sup>,  
80 2020; only 5 patients had censored data for the primary outcome, death in the ICU within 3  
81 months. Given the elapsed time until censoring, the risk of right-censoring bias is low. ANOVA was  
82 used for continuous variables and Fisher's exact test was used for categorical variables at  $\alpha=0.05$ ,  
83 adjusted for multiple comparisons as indicated in the text using the false discovery rate at  $q=0.05$ .  
84 All statistical and graphical analyses were performed on JMP Pro (version 15.2.1; SAS Institute Inc,  
85 Cary, NC, USA).

86

87

#### References

- 88 (1) Agmon-Levin N, Damoiseaux J, Kallenberg C et al. International recommendations for the  
89 assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies.  
90 *Ann Rheum Dis* 2014;73:17-23.
- 91 (2) Copple SS, Jaskowski TD, Giles R, Hill HR. Interpretation of ANA indirect  
92 immunofluorescence test outside the darkroom using NOVA view compared to manual  
93 microscopy. *J Immunol Res* 2014;2014:149316.
- 94 (3) Damoiseaux J, von Muhlen CA, Garcia-de la Torre I et al. International consensus on ANA  
95 patterns (ICAP): the bumpy road towards a consensus on reporting ANA results. *Auto*  
96 *Immun Highlights* 2016;7:1.

- 97 (4) Amlani A, Choi MY, Tarnopolsky M et al. Anti-NT5c1A Autoantibodies as Biomarkers in  
98 Inclusion Body Myositis. *Front Immunol* 2019;10:745.
- 99 (5) Chan EK, Damoiseaux J, Carballo OG et al. Report of the First International Consensus on  
100 Standardized Nomenclature of Antinuclear Antibody HEp-2 Cell Patterns 2014-2015. *Front*  
101 *Immunol* 2015;6:412.  
102  
103